A drug
known as SR9009, which is currently under development at The Scripps Research
Institute (TSRI), increases the level of metabolic activity in skeletal muscles
of mice. Treated mice become lean, develop larger muscles and can run much
longer distances simply by taking SR9009, which mimics the effects of aerobic
exercise. If similar effects can be obtained in people, the reversal of
obesity, metabolic syndrome, and perhaps Type-II diabetes might be the very
welcome result.
The drug
was developed by Professor Thomas Burris, who found that it was able to reduce
obesity in populations of mice. It binds to and activates a protein called
Rev-ErbAα, which influences fat and sugar burning in the liver, production of
fat cells, and the body's inflammatory response.
"We do
have indications that the effects of the drug are very similar to what you see
with someone who has metabolic disorder who starts exercising," Burris
stated in a Voice Of America interview. "They see a decrease in
cholesterol, a decrease in triglycerides, an improvement in glucose metabolism.
And a lot of this is due to transforming the muscle into a more metabolically
active muscle."
http://www.gizmag.com/scripps-drug-sr9009-exercise-mimic/28651/
No comments:
Post a Comment